Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Krystal Biotech, Inc. | krys-10k_20191231.htm |
| EX-32.1 - EX-32.1 - Krystal Biotech, Inc. | krys-ex321_7.htm |
| EX-10.13 - EX-10.13 WHARTON LEASE 3RD AMENDMENT - Krystal Biotech, Inc. | krys-ex1013_80.htm |
| EX-23.1 - EX-23.1 - Krystal Biotech, Inc. | krys-ex231_8.htm |
| EX-31.1 - EX-31.1 - Krystal Biotech, Inc. | krys-ex311_9.htm |
| EX-4.3 - EX-4.3 DESCRIPTION OF COMMON STOCK - Krystal Biotech, Inc. | krys-ex43_128.htm |
| EX-10.14 - EX-10.14 WHARTON LEASE 4TH AMENDMENT - Krystal Biotech, Inc. | krys-ex1014_79.htm |
| EX-31.2 - EX-31.2 - Krystal Biotech, Inc. | krys-ex312_11.htm |
| EX-10.16 - EX-10.16 ASTRA LEASE - Krystal Biotech, Inc. | krys-ex1016_82.htm |
| EX-21.1 - EX-21.1 - Krystal Biotech, Inc. | krys-ex211_78.htm |
| EX-10.15 - EX-10.15 WHARTON LEASE 5TH AMENDMENT - Krystal Biotech, Inc. | krys-ex1015_81.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Krystal Biotech, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: March 10, 2020 |
|
By: |
/s/ Kathryn A. Romano |
|
|
|
|
Kathryn A. Romano |
|
|
|
|
Chief Accounting Officer (Principal Financial and Accounting Officer) |